Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
14.07
-0.25 (-1.75%)
At close: Sep 11, 2026, 4:00 PM EDT
13.87
-0.20 (-1.42%)
After-hours: Sep 11, 2026, 7:39 PM EDT

Monte Rosa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
28.7342.95123.67181.54177.99159.4975.6214.985.761.06----------
Revenue Growth (YoY)
-83.86%-73.07%63.54%1112.27%2990.57%14889.38%--------------
Cost of Revenue
162.36145.41133.7130.57121.44118.06112.86101.57153.96103.73103.3777.9-24.56------
Gross Profit
-133.63-102.46-10.0350.9756.5541.43-37.24-86.6-148.2-102.67-103.37-77.9--24.56------
Selling, General & Admin
48.2245.8244.1842.4641.5943.5643.8742.3842.7541.3339.9445.9742.3937.8235.1224.9622.6920.515.7312.54
Research & Development
---------51.53--17.0789.9459.9777.2678.3272.165.1857.1648.89
Operating Expenses
48.2245.8244.1842.4641.5943.5643.8742.38-8.7841.3339.9463.03132.3397.79112.38103.2894.7985.6872.8861.43
Operating Income
-181.85-148.28-54.218.5114.96-2.13-81.11-128.98-139.42-144-143.31-140.94-132.33-122.34-112.38-103.28-94.79-85.68-72.88-61.43
Interest & Investment Income
17.9415.0912.9411.8511.9911.5610.5710.349.679.349.338.967.736.053.761.790.80.190.050.04
Currency Exchange Gain (Loss)
-0.061.31.481.541.41-0.030.42-0.37-0.19-0.23-0.93-0.43-0.4-0.170.010.230.18-0.25-0.16-0.15
Other Non Operating Income (Expenses)
-------------------0.96-8.64
EBT Excluding Unusual Items
-163.97-131.88-39.7821.928.379.4-70.13-119.01-129.93-134.89-134.91-132.42-125-116.46-108.61-101.27-93.8-85.74-73.96-70.17
Gain (Loss) on Sale of Investments
-----------0.13-0.13-0.13-0.13------
Gain (Loss) on Sale of Assets
--0.060.060.060.06---0.020.020.020.01-0.020.110.110.130.13--
Pretax Income
-163.97-131.88-39.7221.9528.429.46-70.13-119.01-129.93-134.86-135.01-132.52-125.13-116.61-108.5-101.16-93.68-85.61-73.96-70.17
Income Tax Expense
-2.86-1.87-1.11.014.263.312.570.380.480.420.340.360.19-------
Net Income
-161.12-130.01-38.6320.9524.176.15-72.7-119.39-130.41-135.28-135.35-132.88-125.32-116.61-108.5-101.16-93.68-85.61-73.96-70.17
Net Income to Common
-161.12-130.01-38.6320.9524.176.15-72.7-119.39-130.41-135.28-135.35-132.88-125.32-116.61-108.5-101.16-93.68-85.61-73.96-70.17
Net Income Growth (YoY)
--------------------
Shares Outstanding (Basic)
9288838282797468605451494948474747362514
Shares Outstanding (Diluted)
9288838383807468605451494948474747362514
Shares Change (YoY)
11.91%9.92%12.39%22.34%38.55%47.16%43.80%36.96%22.51%12.91%8.83%5.76%4.27%32.28%88.91%240.15%1769.46%2177.87%1548.09%-
EPS (Basic)
-1.74-1.49-0.460.250.290.08-0.98-1.77-2.19-2.50-2.63-2.69-2.58-2.43-2.30-2.17-2.01-2.36-2.96-5.11
EPS (Diluted)
-1.74-1.50-0.460.250.290.08-0.98-1.77-2.19-2.50-2.63-2.69-2.58-2.43-2.30-2.17-2.01-2.36-2.96-5.11
EPS Growth (YoY)
--------------------

Additional Metrics

Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Free Cash Flow
-32.08-19.66-27.5145.0223.8530.4838.01-62.79-67.76-69.81-62.84-122.02-117.66-108.87-105.38-91.38-88.93-82.15-69.1-61.62
Free Cash Flow Per Share
-0.35-0.23-0.331.750.290.380.51-0.93-1.14-1.29-1.22-2.47-2.42-2.27-2.23-1.96-1.91-2.27-2.76-4.49
Gross Margin
--238.54%-8.11%28.08%31.77%25.98%-49.25%-------------
Operating Margin
-633.04%-345.21%-43.83%4.69%8.40%-1.33%-107.26%-861.29%-2420.91%-13533.74%----------
Profit Margin
-560.85%-302.69%-31.23%11.54%13.58%3.86%-96.14%-797.25%-2264.53%-12714.47%----------
Free Cash Flow Margin
-111.66%-45.76%-22.23%79.88%13.40%19.11%50.26%-419.27%-1176.56%-6560.62%----------
EBITDA
-173.73-139.94-45.8516.8423.36.14-72.99-121.07-131.78-137.03-137.09-133.09-127.69-118.2-108.64-102.2-91.76-83.07-70.75-59.89
EBITDA Margin
---37.08%9.28%13.09%3.85%-96.52%-------------
D&A For EBITDA
8.138.348.368.338.348.278.127.917.646.976.227.854.654.143.751.083.032.612.131.55
EBIT
-181.85-148.28-54.218.5114.96-2.13-81.11-128.98-139.42-144-143.31-140.94-132.33-122.34-112.38-103.28-94.79-85.68-72.88-61.43
EBIT Margin
---43.83%4.69%8.40%-1.33%-107.26%-------------
Effective Tax Rate
---4.59%14.97%34.97%--------------
SEC Filings: 10-K · 10-Q